Farxiga (dapagliflozin) works by blocking a protein in your kidneys that normally recycles glucose back into your bloodstream. By shutting down this recycling process, the drug forces excess glucose out through your urine, lowering blood sugar without relying on insulin. But that kidney-level action also triggers a cascade of secondary effects that protect your heart and kidneys, which is why Farxiga is now approved for conditions well beyond type 2 diabetes.
The Kidney Mechanism Behind Farxiga
Your kidneys filter about 180 grams of glucose from your blood every day. Normally, a transport protein called SGLT2 reabsorbs most of that glucose in the early part of the kidney’s filtration tubes (the proximal tubules) and sends it back into your bloodstream. Farxiga blocks SGLT2, reducing glucose reabsorption by 30% to 60%. The glucose that would have been recycled instead stays in your urine and leaves your body.
This mechanism is completely independent of insulin. Farxiga doesn’t stimulate your pancreas to produce more insulin or make your cells more sensitive to it. It simply lowers the threshold at which your kidneys start spilling glucose into urine. That’s a meaningful distinction because it means Farxiga carries very little risk of causing low blood sugar on its own, unlike some older diabetes medications.
After you take a tablet, the drug reaches peak levels in your blood within about two hours. In clinical trials, patients taking Farxiga alongside metformin saw fasting blood sugar drop by 12 to 16.5 mg/dL within the first week, compared to essentially no change with a placebo.
How It Protects the Heart
Farxiga’s heart benefits surprised researchers, and they go far beyond blood sugar control. The drug is now FDA-approved to reduce the risk of cardiovascular death and hospitalization in adults with heart failure, regardless of whether they have diabetes.
The most straightforward cardiac benefit is a mild diuretic effect. Because Farxiga causes your kidneys to excrete more glucose, water follows along with it. This gently reduces blood volume, which lowers the workload on your heart. Less volume means less pressure filling the heart chambers, reduced oxygen demand, and less strain on the cardiac muscle. In imaging studies, patients on SGLT2 inhibitors showed improved pumping efficiency and smaller heart chamber volumes.
At a deeper level, Farxiga appears to shift the heart’s energy metabolism in a favorable direction. A struggling heart tends to revert to less efficient fuel sources. SGLT2 inhibitors help redirect the heart toward burning ketone bodies and fatty acids, which produce more energy per unit of oxygen consumed. This metabolic shift improves the heart’s energy supply and supports better function even in damaged tissue. The drug also reduces oxidative stress and inflammation in heart muscle cells, two processes that drive the progressive scarring and stiffening known as cardiac remodeling. In animal models, dapagliflozin specifically reduced fibrosis and inflammation through multiple cellular pathways.
How It Slows Kidney Disease
Farxiga is approved to reduce the risk of kidney function decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression. The kidney protection stems from a feedback loop built into your nephrons.
When Farxiga blocks glucose reabsorption, more sodium also passes further down the kidney tubule. Specialized sensor cells detect this extra sodium and respond by constricting the tiny artery feeding each filtering unit (glomerulus). This reduces the pressure inside the glomerulus. High intraglomerular pressure is one of the main forces that damages kidney filters over time, so lowering it slows the progression of kidney disease.
The clinical results are substantial. In trials, dapagliflozin decreased new-onset protein leakage in the urine (a key marker of kidney damage) by 21%, and more severe protein leakage by 46%. Across both clinical trials and real-world studies, SGLT2 inhibitors consistently slow the rate at which kidney filtration declines over time.
What Farxiga Is Approved to Treat
Farxiga currently carries four FDA-approved indications:
- Type 2 diabetes: as an add-on to diet and exercise for blood sugar control
- Heart failure: to reduce the risk of cardiovascular death and hospitalization, in adults with heart failure regardless of diabetes status
- Chronic kidney disease: to slow kidney decline and reduce cardiovascular events in adults with CKD at risk of progression
- Cardiovascular risk reduction in type 2 diabetes: to reduce heart failure hospitalization in adults with type 2 diabetes who have established cardiovascular disease or multiple risk factors
The heart failure and CKD indications do not require a diabetes diagnosis, which reflects how the drug’s benefits extend well beyond glucose control.
Dosing: 5 mg vs. 10 mg
For type 2 diabetes, Farxiga typically starts at 5 mg once daily, taken in the morning. If you tolerate it well and need better blood sugar control, your dose can increase to 10 mg. For heart failure, chronic kidney disease, and cardiovascular risk reduction, the standard dose is 10 mg once daily from the start.
Kidney function determines whether Farxiga can be initiated and how well it works for blood sugar. If your estimated kidney filtration rate (eGFR) is 45 or above, the drug works at full effectiveness for glucose control. Between 25 and 44, Farxiga is no longer recommended for blood sugar management because too little glucose is being filtered for the drug to make a meaningful difference. It can still be used at 10 mg daily for heart and kidney protection. Below 25, starting the drug is not recommended, though patients already taking it can continue for its heart and kidney benefits.
Common Side Effects and Why They Happen
The most predictable side effect of Farxiga is a direct consequence of how it works. By increasing glucose in your urine, the drug creates a more hospitable environment for yeast. In pooled clinical trial data from the FDA, genital yeast infections affected about 7% to 8% of women taking Farxiga, compared to 1.5% on placebo. For men, the rate was roughly 3% versus 0.3% on placebo. These infections are typically mild and treatable, but they’re common enough that you should know to expect the possibility.
Urinary tract infections also occur at modestly higher rates: about 4% to 6% of patients on Farxiga versus 3.7% on placebo. The sugar-rich urine likely contributes here as well, though the increase is smaller than with yeast infections.
Because Farxiga has a mild diuretic effect, some people experience increased urination, thirst, or lightheadedness from lower blood pressure. Staying well hydrated helps offset this effect, particularly when first starting the medication or during hot weather. The diuretic action is gentler than traditional water pills because it pulls fluid primarily from the space between cells rather than depleting overall blood volume as aggressively.
A rarer but more serious concern is diabetic ketoacidosis (DKA), which can occasionally occur even when blood sugar levels appear normal or only mildly elevated. This atypical presentation can delay recognition. The risk is low but worth understanding, particularly if you’re on insulin, eating very little, or about to undergo surgery.